Samarium-153 and technetium-99m-labeled monoclonal antibodies in angiogenesis for tumor visualization and inhibition.
| Autor: | Bouziotis P; National Center for Scientific Research Demokritos, 15310 Aghia Paraskevi, Athens, Greece., Fani M, Archimandritis SC, Loundos G, Paravatou M, Bicknell R, Harris AL, Xanthopoulos S, Stratis N, Varvarigou AD |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Anticancer research [Anticancer Res] 2003 May-Jun; Vol. 23 (3A), pp. 2167-71. |
| Abstrakt: | Background: Angiogenesis is the development of new blood vessels from pre-existing ones. Vascular endothelial growth factor (VEGF) is one of the most important angiogenic activators. Our studies are focused on the detection of VEGF by use of radiolabeled anti-endothelial monoclonal antibodies, which have the ability to localize in newly-formed vasculature of a cancerous origin. Materials and Methods: The anti-endothelial monoclonal antibody VG76e was labeled with Samarium-153 and Technetium-99m. Biodistribution of the radiolabeled species was assessed in normal female Swiss mice, while tumor uptake was also evaluated. Results: VG76e was labeled with 99mTc and 153Sm, resulting in a single product with a labeling yield of over 95%. Biodistribution studies showed non-specific uptake in any organ, with elimination via the hepatobiliary system. Finally, satisfactory tumor uptake was observed for both radiolabeled derivatives. Conclusion: Monoclonal antibodies raised against epithelial growth factors or their receptors, when labeled with appropriate radionuclides, may be a useful tool for early tumor detection and eventually for therapy. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|